Dr Reddy’s Laboratories Limited has reported 76 per cent growth in profit after tax to ₹764.2 crore for quarter ended March 31, 2020 against ₹434.4 crore in the corresponding period last year.
Revenues for the quarter under discussion was up by 10 per cent to ₹4,431.8 crore against ₹4,016.6 crore in Q4 of last fiscal, a press release said here on Wednesday.
Commenting on the results, co-Chairman and managing director of the company GV Prasad said, “FY ‘20 has been a positive year for the company.” “Progress made during the year includes VAI (voluntary action initiated) status for CTO 6, healthy product pipeline build-up, productivity improvement, and strong financial performance across our businesses,” he said.
The revenues from global generics stood at Rs. 3,640 crore a YoY growth of 20 per cent. The Pharmaceutical Services and Active Ingredients (PSAI) segment revenues were up six per cent at rs 719.5 crore against ₹676.5 crore in Q4 of FY19.
For the full financial year 2019-20, revenues were up 13 per cent over FY ‘19 while profit after tax was at ₹1,950 crore up four per cent over previous year, Dr Reddy's said.
{{/usCountry}}For the full financial year 2019-20, revenues were up 13 per cent over FY ‘19 while profit after tax was at ₹1,950 crore up four per cent over previous year, Dr Reddy's said.
{{/usCountry}}